Infection risk of rituximab monotherapy versus combination therapy with rituximab and mycophenolic acid in systemic sclerosis: A retrospective cohort study

J Am Acad Dermatol. 2025 May;92(5):1151-1153. doi: 10.1016/j.jaad.2025.01.054. Epub 2025 Jan 27.

¹ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; University of Massachusetts Chan Medical School, Worcester, Massachusetts.
³ College of Information Science and Technology, Pennsylvania State University, University Park, Pennsylvania.
⁴ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: jsmith@bwh.harvard.edu.

No abstract available

Keywords: complex medical dermatology; immunomodulation; infection; mycophenolic acid; rituximab; systemic sclerosis.

Grants and funding